Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Oncology consultancy company Physiomics (LON: PYC) shares are gaining slightly on Tuesday after the company revealed it has been awarded a first contract by new client Numab Therapeutics.
On Monday, Physiomics share price fell over 8.5% after it provided a trading update, lowering guidance after Covid related project delays.
Today, it has begun to claw back some of those losses, trading at 5.95p, up 1.71%.
Numab Therapeutics is a biopharmaceutical company based in Zurich, Switzerland, developing multi-specific biotherapeutics for chronic inflammation and cancer.
Physiomics said it has “recent significant experience of the mathematical modelling of multi-specific pharmaceuticals which it will bring to bear on an undisclosed Numab compound in this project that is expected to last around three months.”
“We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team,” said the AIM-listed company's CEO, Dr Jim Millen.
Physiomics shares are traded on the London stock exchange's AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are Physiomics shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .